Print
|
Close
Study of PYX-106 in Solid Tumors
Active:
Yes
Cancer Type:
Uterine Cancer
NCT ID:
NCT05718557
Trial Phases:
Phase I
Protocol IDs:
PYX-106-101 (primary)
NCI-2023-03477
2022-002306-24
2023-509686-21-00
Eligibility:
18 Years and older, Male and Female
Study Type:
Treatment
Study Sponsor:
Pyxis Oncology, Inc
NCI Full Details:
http://clinicaltrials.gov/show/NCT05718557
Summary
The primary objective of this study is to determine the recommended dose(s) of PYX-106 in
participants with relapsed/refractory solid tumors.
Treatment Sites in Georgia
Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.